Investment Thesis
ImmunityBio exhibits severe financial distress with negative stockholders' equity of -$870M, catastrophic net losses of -$632.8M against minimal $44.2M revenue, and negative free cash flow of -$77.1M that will deplete cash reserves within 3 years. The company demonstrates no revenue growth momentum and profitability metrics so negative that fundamental business model viability is in question.
Strengths
- $205.2M cash balance provides near-term liquidity buffer for operations
- Current ratio of 6.67x indicates adequate short-term liquidity to meet immediate obligations
- EPS improved 38.7% YoY showing reduction in loss magnitude per share
Risks
- Negative stockholders' equity of -$870M indicates technical insolvency and material bankruptcy risk
- Negative free cash flow of -$77.1M at current burn rate exhausts cash in <3 years without profitability inflection
- Zero revenue growth with operating losses of -$69.8M reveals fundamental business model dysfunction
- Net margin of -1431.4% suggests unsustainable cost structure relative to revenue base
- Likely need for dilutive equity raises as cash burns, creating shareholder dilution risk
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway calculation
- Revenue growth rate and major product pipeline approval timeline
- Operating expense trajectory and path to gross margin expansion
- Debt refinancing needs and covenant compliance status
- Capital raise announcements and terms of dilution to existing shareholders
Financial Metrics
Revenue
44.2M
Net Income
-632.8M
EPS (Diluted)
$-0.62
Free Cash Flow
-77.1M
Total Assets
646.6M
Cash
205.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-157.9%
Net Margin
-1,431.4%
ROE
N/A
ROA
-97.9%
FCF Margin
-174.5%
Balance Sheet & Liquidity
Current Ratio
6.67x
Quick Ratio
6.66x
Debt/Equity
N/A
Debt/Assets
234.4%
Interest Coverage
-1.15x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:38:12.635397 |
Data as of: 2026-03-31 |
Powered by Claude AI